Terms: = Breast cancer AND RB1, OSRC, ENSG00000139687, 5925, RB, P06400 AND Treatment
398 results:
1. Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic breast cancer Treated With Abemaciclib: Data From the SCRUM-Japan cancer Genome Screening Project.
Hattori M; Serelli-Lee V; Naito Y; Yamanaka T; Yasojima H; Nakamura R; Fujisawa T; Imai M; Nakamura Y; Bando H; Kawaguchi T; Yoshino T; Iwata H
JCO Precis Oncol; 2024 Apr; 8():e2300647. PubMed ID: 38635933
[TBL] [Abstract] [Full Text] [Related]
2. Comprehensive Transcriptomic Analysis of EWSR1::WT1 Targets Identifies CDK4/6 Inhibitors as an Effective Therapy for Desmoplastic Small Round Cell Tumors.
Magrath JW; Sampath SS; Flinchum DA; Hartono AB; Goldberg IN; Boehling JR; Savkovic SD; Lee SB
Cancer Res; 2024 May; 84(9):1426-1442. PubMed ID: 38588409
[TBL] [Abstract] [Full Text] [Related]
3. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer.
Lin CC; Chang TC; Wang Y; Guo L; Gao Y; Bikorimana E; Lemoff A; Fang YV; Zhang H; Zhang Y; Ye D; Soria-Bretones I; Servetto A; Lee KM; Luo X; Otto JJ; Akamatsu H; Napolitano F; Mani R; Cescon DW; Xu L; Xie Y; Mendell JT; Hanker AB; Arteaga CL
Nat Commun; 2024 Mar; 15(1):2287. PubMed ID: 38480701
[TBL] [Abstract] [Full Text] [Related]
4. CD63
Sun J; Du R; Li X; Liu C; Wang D; He X; Li G; Zhang K; Wang S; Hao Q; Zhang Y; Li M; Gao Y; Zhang C
Cancer Lett; 2024 Apr; 588():216747. PubMed ID: 38403110
[TBL] [Abstract] [Full Text] [Related]
5. Drug-resilient cancer Cell Phenotype Is Acquired via Polyploidization Associated with Early Stress Response Coupled to HIF2α Transcriptional Regulation.
Carroll C; Manaprasertsak A; Boffelli Castro A; van den Bos H; Spierings DCJ; Wardenaar R; Bukkuri A; Engström N; Baratchart E; Yang M; Biloglav A; Cornwallis CK; Johansson B; Hagerling C; Arsenian-Henriksson M; Paulsson K; Amend SR; Mohlin S; Foijer F; McIntyre A; Pienta KJ; Hammarlund EU
Cancer Res Commun; 2024 Mar; 4(3):691-705. PubMed ID: 38385626
[TBL] [Abstract] [Full Text] [Related]
6. Encapsulated Rose Bengal Enhances the Photodynamic treatment of Triple-Negative breast cancer Cells.
Uddin MMN; Bekmukhametova A; Antony A; Barman SK; Houang J; Wu MJ; Hook JM; George L; Wuhrer R; Mawad D; Ta D; Ruprai H; Lauto A
Molecules; 2024 Jan; 29(2):. PubMed ID: 38276623
[TBL] [Abstract] [Full Text] [Related]
7. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced breast cancer.
Ji Y; Schiller H; Yang S; Quinlan M; Darstein C; Huth F; Winter S; Chakraborty A
Clin Pharmacokinet; 2024 Feb; 63(2):155-170. PubMed ID: 38244190
[TBL] [Abstract] [Full Text] [Related]
8. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
Liu Q; Zhang J; Guo C; Wang M; Wang C; Yan Y; Sun L; Wang D; Zhang L; Yu H; Hou L; Wu C; Zhu Y; Jiang G; Zhu H; Zhou Y; Fang S; Zhang T; Hu L; Li J; Liu Y; Zhang H; Zhang B; Ding L; Robles AI; Rodriguez H; Gao D; Ji H; Zhou H; Zhang P
Cell; 2024 Jan; 187(1):184-203.e28. PubMed ID: 38181741
[TBL] [Abstract] [Full Text] [Related]
9. Interplay of oxidative stress, cellular communication and signaling pathways in cancer.
Iqbal MJ; Kabeer A; Abbas Z; Siddiqui HA; Calina D; Sharifi-Rad J; Cho WC
Cell Commun Signal; 2024 Jan; 22(1):7. PubMed ID: 38167159
[TBL] [Abstract] [Full Text] [Related]
10. The dual activity of CaONPs as a cancer treatment substance and at the same time resistance to harmful microbes.
Awaad A; Olama ZA; El-Subruiti GM; Ali SM
Sci Rep; 2023 Dec; 13(1):22940. PubMed ID: 38135693
[TBL] [Abstract] [Full Text] [Related]
11. CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.
Pita JM; Raspé E; Coulonval K; Decaussin-Petrucci M; Tarabichi M; Dom G; Libert F; Craciun L; Andry G; Wicquart L; Leteurtre E; Trésallet C; Marlow LA; Copland JA; Durante C; Maenhaut C; Cavaco BM; Dumont JE; Costante G; Roger PP
Front Endocrinol (Lausanne); 2023; 14():1247542. PubMed ID: 37964967
[TBL] [Abstract] [Full Text] [Related]
12. Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4/6 inhibitors in breast cancer.
Kim S; Armand J; Safonov A; Zhang M; Soni RK; Schwartz G; McGuinness JE; Hibshoosh H; Razavi P; Kim M; Chandarlapaty S; Yang HW
Cell Rep; 2023 Nov; 42(11):113198. PubMed ID: 37865915
[TBL] [Abstract] [Full Text] [Related]
13. Photodynamic treatment of Human breast and Prostate cancer Cells Using Rose Bengal-Encapsulated Nanoparticles.
Uddin MMN; Bekmukhametova A; Antony A; Barman SK; Houang J; Wu MJ; Hook J; George L; Wuhrer R; Mawad D; Ta D; Lauto A
Molecules; 2023 Oct; 28(19):. PubMed ID: 37836744
[TBL] [Abstract] [Full Text] [Related]
14. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
André F; Su F; Solovieff N; Hortobagyi G; Chia S; Neven P; Bardia A; Tripathy D; Lu YS; Lteif A; Taran T; Babbar N; Slamon D; Arteaga CL
Ann Oncol; 2023 Nov; 34(11):1003-1014. PubMed ID: 37673211
[TBL] [Abstract] [Full Text] [Related]
15. CRISPR screen identifies GATAD1 as a synthetic lethal target with CDK4/6 inhibitors in estrogen receptor-positive breast cancer.
Liu W; Zhang R; Yu X; Zhang Y; Kang T; Liao D
Med Oncol; 2023 Aug; 40(9):267. PubMed ID: 37567972
[TBL] [Abstract] [Full Text] [Related]
16. Hybrid planning techniques for early-stage left-sided breast cancer: dose distribution analysis and estimation of projected secondary cancer-relative risk.
Racka I; Majewska K; Winiecki J; Kiluk K
Acta Oncol; 2023 Aug; 62(8):932-941. PubMed ID: 37516978
[TBL] [Abstract] [Full Text] [Related]
17. Combined doxorubicin and arctigenin treatment induce cell cycle arrest-associated cell death by promoting doxorubicin uptake in doxorubicin-resistant breast cancer cells.
Lee MG; Lee KS; Nam KS
IUBMB Life; 2023 Sep; 75(9):765-777. PubMed ID: 37492896
[TBL] [Abstract] [Full Text] [Related]
18. Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Park YH; Im SA; Park K; Wen J; Lee KH; Choi YL; Lee WC; Min A; Bonato V; Park S; Ram S; Lee DW; Kim JY; Lee SK; Lee WW; Lee J; Kim M; Kim HS; Weinrich SL; Ryu HS; Kim TY; Dann S; Kim YJ; Fernandez DR; Koh J; Wang S; Park SY; Deng S; Powell E; Ravi RK; Bienkowska J; Rejto PA; Park WY; Kan Z
Genome Med; 2023 Jul; 15(1):55. PubMed ID: 37475004
[TBL] [Abstract] [Full Text] [Related]
19. Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer.
Jiang Z; Ju Y; Ali A; Chung PED; Skowron P; Wang DY; Shrestha M; Li H; Liu JC; Vorobieva I; Ghanbari-Azarnier R; Mwewa E; Koritzinsky M; Ben-David Y; Woodgett JR; Perou CM; Dupuy A; Bader GD; Egan SE; Taylor MD; Zacksenhaus E
Nat Commun; 2023 Jul; 14(1):4313. PubMed ID: 37463901
[TBL] [Abstract] [Full Text] [Related]
20. [Mammary myofibroblastoma: a clinicopathological analysis of fifteen cases].
Ren HY; He X; Lyu H; Huang HF; Liu YQ; Wei N; Zhang L; Li WC; Li HX
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):683-689. PubMed ID: 37408398
[No Abstract] [Full Text] [Related]
[Next]
